Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Items 501–600 of 617
Cardiac involvement in the dystrophinopathies
Russell, M. W. W., Townsend, D., & Metzger, J. M. (2008) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-2008-00037 · Cited by 2
“…and genetic characterization of Becker and Duchenne muscular dystrophy patients have provided new evidence on the importance of various domains within dystrophin and pointed to sizeable deletions in the spectrin-like rod domain of dystrophin that still retained significant function [33,56,57].”
Optimization of Internally Deleted Dystrophin Constructs
Reza, M., Laval, S. H., Roos, A., Carr, S., & Lochmüller, H. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.026 · Cited by 3
Preand posttranscriptional genetic information modification in muscular dystrophy treatment
Антонович, Я. И., Deev, R. V., Solovyeva, V. V., Rizvanov, A. A., & Isaev, A. A. (2016) · Genes and Cells · doi:10.23868/gc120570 · Cited by 2
Genetic modelling of muscular dystrophies
Hammerbeck-Ward, C. L., & Davies, K. E. (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00005.x · Cited by 3
Self-citationDickson, G., & Brown, S. (1995) · Springer eBooks · doi:10.1007/978-94-011-0547-7_14 · Cited by 2
Principes des approches thérapeutiques des DMD
Amthor, H. (2015) · Archives de Pédiatrie · doi:10.1016/s0929-693x(16)30011-2 · Cited by 2
2015 ASHG Awards and Addresses
(2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.01.013 · Cited by 2
CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review
Khatibi, S., Sahebkar, A., & Aghaee‐Bakhtiari, S. H. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200621161610 · Cited by 3
Mongkolchaipak, S., Piyamongkol, S., Teekaput, C., Sirapat, R., Suriya, W., Pantasri, T., Tongsong, T., & Piyamongkol, W. (2021) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog4805187 · Cited by 2
Adeno-associated Virus and AAV Vectors for Gene Delivery
Carter, B., Burstein, H., & PELUSO, R. W. (2003) · CRC Press eBooks · doi:10.1201/9780824758608.ch5 · Cited by 3
Escolar, D. M., & Leshner, R. T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0435-8.00093-7 · Cited by 3
Multiplicity of abnormal dystrophin in Becker muscular dystrophy
Hori, S., Ohtani, S., Shimizu, T., Ibi, T., Sahashi, K., Nonaka, I., Miyamoto, K., & Tanabe, H. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90350-6 · Cited by 2
Retroviral-Mediated Gene Transfer and Duchenne Muscular Dystrophy
Dunckley, M. G., & Dickson, G. (1994) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4684-6822-9_22 · Cited by 2
Баранов, В. С., Baranov, A. N., & Zelenin, A. V. (2001) · Russian Journal of Genetics · doi:10.1023/a:1016765313810 · Cited by 2
“3-kb mini-gene cDNA should be used for GT studies [22].”
MethodThe Global State of Genome EditingPreprint
Siwo, G. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/341198 · Cited by 2
Jayaraman, D., & Ghosh, P. S. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001618 · Cited by 2
Proteomics-based evaluation of AAV dystrophin gene therapy outcomes in mdx skeletal muscle
Johnson, E. E., Reyes, T. R., Chamberlain, J. S., Ervasti, J. M., & Tasfaout, H. (2025) · JCI Insight · doi:10.1172/jci.insight.197759 · Cited by 1
Owusu, L., Kim, S., Patel, H., Foltz, S. J., Chan, G. N. Y., Kim, K. H., Kopen, A., Yang, L., Lawlor, M. W., Buss, N. A. P. S., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102901 · Cited by 1
“…in cases of significant internal truncation, as observed in Becker muscular dystrophy (BMD), where the disease phenotype is milder relative to DMD. 26,27 Therefore, dystrophin can be rationally miniaturized (resulting in synthetic “microdystrophins” [ μ Dys] or “mini-dystrophins”) to achieve…”
InfluentialBridging science and hope: the evolving story of gene therapy for neuromuscular diseases
Wein, N., & Barthélémy, F. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1765367 · Cited by 1
“In the case of DMD, the discovery of a truncated dystrophin, lacking 70% of the native protein sequence but partially functional, in a 61-year-old ambulant patient was a game changer (England et al., 1990).”
Microdystrophins partially rescue deficits of Duchenne muscular dystrophy iPSC-cardiomyocytes
Keegan, A. R., Gonzalez, A. F. G. S., Zhang, R., Doan, H., Torres-Bigio, S. I., Lau, F., Ly, K. N., Lai, E. C., Mamuyac, L. C., Bhimaraju, S., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201801 · Cited by 2
“34 In this study, we compared three microdystrophins (microDYS1, microDYS2, and microDYS3) with miniDYS in DMD iPSC-CMs.”
Investigational treatments and therapeutic targets in Becker muscular dystrophy
Matsuo, M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1057117 · Cited by 1
“Thus far, 36 patients have been reported to our knowledge [8,67-77].”
BackgroundGene and Cell Therapies for Muscular Dystrophies
Benedetti, S., Cossu, G., & Tedesco, F. S. (2015) · CRC Press eBooks · doi:10.1201/b18002-46 · Cited by 1
“To this end, the discovery that in humans shorter dystrophins led to a milder dystrophic phenotype [139] fuelled the idea that mini- (mDYS) or micro-dystrophins (μDYSs) containing only some spectrin-like domains could be still functional.”
BackgroundMolecular and genetic aspects of Duchenne muscular dystrophy
Grishko, V. I., & Лившиц, Л. А. (1995) · Biopolymers and Cell · doi:10.7124/bc.0003e8 · Cited by 1
Dystrophie musculaire de Duchenne : état actuel et perspectives thérapeutiques
Guen, Y. T. L., Gall, T. L., Laurent, V., d’Arbonneau, F., Braun, S., & Montier, T. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.10.019 · Cited by 2
Upadhyay, V., Ray, S., Panja, S., Saviola, A. J., Maluf, N. K., & Mallela, K. M. G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108002 · Cited by 1
“However, many of these spectrin repeats can be removed, as Becker muscular dystrophy patients with less severe symptoms have large deletions in regions coding for spectrin repeats (60 – 62).”
Asadi, S. (2017) · SOJ Immunology · doi:10.15226/2372-0948/5/2/00161 · Cited by 1
Genome Editing Therapy for Duchenne Muscular Dystrophy
Gao, Y., Xu, L. M., & Han, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00014-4 · Cited by 1
Gene Replacement Therapy for Duchenne Muscular Dystrophy
Hollinger, K., Crudele, J. M., & Chamberlain, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_18 · Cited by 1
Single-Cell Editing: The CRISPR/Cas9 and Applications
Dilshad, E., Zahra, N., Nooruddin, Z., Butt, A. A., & Bakhtiar, S. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814919-5.00018-x · Cited by 1
Muscular Dystrophies and Allied Disorders I
(2020) · Elsevier eBooks · doi:10.1016/b978-0-7020-7471-4.00010-0 · Cited by 1
Rybalka, E. (2007) · Victoria University Research Repository (Victoria University) · Cited by 4
Sakthivel, M. S. M. (2013) · Shodhganga · Cited by 1
Strategies for Molecular Therapy of Duchenne Muscular Dystrophy
Dunant, P. (2003) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.1242 · Cited by 2
Réflexions à propos des récents progrès dans la génétique moléculaire des myopathies
Jc, K. (1995) · Archives de Pédiatrie · doi:10.1016/0929-693x(96)81238-3 · Cited by 1
Un saut symbolique mais encourageant dans le traitement de la myopathie de Duchenne
Kaplan, J., Chelly, J., & Garcı́a, L. (2008) · médecine/sciences · doi:10.1051/medsci/2008242215 · Cited by 1
“trophine où la protéine est amputée de 46 % [7].”
Prospects of gene therapy for genetic skeletal muscle disease
Karpati, G., & Lochmüller, H. (1996) · Transfusion Science · doi:10.1016/0955-3886(95)00058-5 · Cited by 1
Duchenne muscular dystrophy : mutation profiling in view of the emerging gene-based therapies
Esterhuizen, A. I. (2010) · Open University of Cape Town (University of Cape Town) · Cited by 1
Analysis of Protein Expression in Muscular Dystrophies
Anderson, L. V. B. (2003) · Humana Press eBooks · doi:10.1385/1-59259-138-8:319 · Cited by 1
Gene transfer therapy for heritable disease: cell and expression targeting
Mitani, K., Clemens, P. R., Moseley, A., & Caskey, C. T. (1993) · Springer eBooks · doi:10.1007/978-94-011-1240-6_10 · Cited by 1
Warner, L. E., & Chamberlain, J. S. (2006) · Wiley eBooks · doi:10.1038/npg.els.0005684 · Cited by 1
DYSTROPHIN PROTEIN COMPLEX ASSEMBLY IN LIVING CELLS
Draviam, R. A. (2006) · D-Scholarship@Pitt (University of Pittsburgh)
Fibrotic pathways in the dystrophin deficient heart
Wakefield, A. (2009) · University of Southern Queensland research data collection · doi:10.26192/q0x98
Silva, M. C. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-01112013-093410
Duchenne Muscular Dystrophy: Therapeutic Approaches to Restore Dystrophin
Spitali, P., & Aartsma-Rus, A. M. (2012) · InTech eBooks · doi:10.5772/31232
“These smaller dystrophin coding sequences, called mini-dystrophins (mDYS) and microdystrophins (μDys), were designed based on the observations that BMD patients with minor dystrophic phenotype can carry very large deletions (England et al., 1990).”
BackgroundHow Mutant Alleles Affect the Phenotype
Maroni, G. (2000) · Wiley eBooks · doi:10.1002/9780470760079.ch6
Partridge, T. A. (2006) · Wiley eBooks · doi:10.1038/npg.els.0005753
The Membrane-Associated Cytoskeleton and Exoskeleton
Bloch, R. J. (1996) · Springer eBooks · doi:10.1007/978-1-4613-1143-0_3 · Cited by 1
Shami, A. (2014) · Lund University Publications (Lund University)
Thérapie génique des dystrophies musculaires
Vincent, N. (1999) · Annales de l Institut Pasteur / Actualités · doi:10.1016/s0924-4204(00)80004-9
Immunostaining of dystrophin using catalyzed signal amplification
Hoshino, S., Ohkoshi, N., Watanabe, M., & Shoji, S. (1999) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199909)22:9<1298::aid-mus23>3.0.co;2-8
Yu, C.-Y., Wang, B., Wang, Z., Cao, Z., Li, J., & Xiao, X. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.556
Inherited Muscle Disease: Gene Therapy
Partridge, T. A. (2007) · Wiley eBooks · doi:10.1002/9780470015902.a0005753.pub2
Crisp, A., Goyenvalle, A., & Davies, K. E. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_13
“In one reported case, there was a deletion of 46% of the gene comprising around 67% of the central rod domain of dystrophin, and the patient was still ambulant at 61 years of age [ 83 ] .”
BackgroundSelf-citationCrain, J. (2014) · University of Minnesota Digital Conservancy (University of Minnesota)
2015 William Allan Award Introduction: Kay E. Davies 1
Fisch, G. S. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.01.003
Davies, K. E. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.01.007
“Nevertheless, it is important to note that BMD patients who lack the nNOS binding site are often mildly affected, and therefore the lack of nNOS binding might not be very significant.(24) This could also be compensated by treatment with PDE5 inhibitors, such as tadalafil.”
BackgroundSelf-citationIntroduction to molecular biology for the nephrologist.
Harris, H. W., & Paredes, A. L. (1992) · PubMed
Goyenvalle, A., Vulin, A., Fougerousse, F., Kaplan, J., Garcı́a, L., & Danos, O. (2016)
Schindl, R., Mayer, K., & Aigner, K. (1975) · PubMed
Duan, D., Emter, C. A., Lai, Y., Yang, H. T., Hakim, C. H., & Yue, Y. (2015)
Quenneville, S. (2007) · Corpus Université Laval (Université Laval)
Muscular Dystrophy Gene Therapy in Small Animal Models
Qiao, C., & Xiao, X. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_4
“The mini-dystrophin genes, as small as only one-third of the 11-kb fulllength dystrophin coding sequence, are significantly smaller than the 6.3-kb Becker-form mini-dystrophin gene ( England et al. 1990 ) that was widely used in transgenic and gene therapy studies in mdx mice (Ragot et al. 1993).”
BackgroundInfluentialDelineation of Duchenne muscular dystrophy gene therapy using genetically engineered mice
Wasala, N. B. (2016) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/57275
Fall, A., Johnsen, R. D., Honeyman, K., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2015)
Hoffman, D. B. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Sirsi, S. R., & Lutz, G. J. (2007) · iDEA - Drexel University Institutional Repository · doi:10.17918/etd-1869
Nelson, D. M. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Treatment and Management of Muscular Dystrophies
Rocha, C. T., & Escolar, D. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00020-2
Taylor, M. B. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738401805.793578644
Speer, A., & Oexle, K. (2000) · Springer eBooks · doi:10.1007/978-3-642-57043-8_1
Sahenk, Z., & Rodino‐Klapac, L. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6567-6_56
Neuromuscular Cardiomyopathies
Kamdar, F. D., Mammen, P. P. A., & Garry, D. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-44577-9_12
Lessons learned from developing an oligonucleotide drug for a rare disease
Soblechero‐Martín, P., & Arechavala‐Gomeza, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00002-6
Ludueña, R. F. (1997) · Springer eBooks · doi:10.1007/978-3-642-95866-3_14
(1990) · The Lancet · doi:10.1016/0140-6736(90)90300-t
Muscular Dystrophies and Allied Disorders I
(2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-4340-6.00010-0
(2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-2593-1.50029-2
Ghosh, P. S., & Darras, B. T. (2023) · Current clinical neurology · doi:10.1007/978-3-031-44009-0_2 · Cited by 1
Molecular Genetic Therapies in the Muscular Dystrophies
Nicolau, S., & Flanigan, K. M. (2023) · Current clinical neurology · doi:10.1007/978-3-031-44009-0_18
Muscular Dystrophy: Mutations in the Dystrophin Gene
Agarwal, A., Verma, K., Tyagi, S., Gupta, K., Sk, G., Sharma, S., & Kumar, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-9404-5_15
Kingsmore, S. F., Baun, D., Tobin, L., Nguyen, H. V., Arenchild, M., Juarez, E. F., Kiernan, E. A., Lesser, D. J., Wong, E., Prilutsky, D., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4049883/v1
Warman‐Chardon, J., Jasmin, B. J., Kothary, R., & Parks, R. J. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602241304993 · Cited by 2
Challenges in developing gene therapy against Duchenne muscular dystrophy
Kurshakova, E. V., Levchenko, O. A., & Лавров, А. В. (2025) · Genes and Cells · doi:10.17816/gc641931 · Cited by 1
Duchenne and Becker Muscular Dystrophy
McMillan, H. J., & Darras, B. T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00167-0
Biswas, D. D., Han, N. H., Rodríguez, M. Y. H., Lee, J., Abdelbarr, S. M., Scarrow, E. R., & ElMallah, M. K. (2025) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2025.104513
Владимирович, М. А., Анатольевна, С. С., Nikitin, S., Adyan, T., Akhkiamova, M., Borovikov, A. O., Buharova, T., Efimova, I. E., Zharkov, P., Kadyshev, V. V., et al. (2026) · doi:10.29039/978-5-94472-329-1-02-2026
The function of Activin receptor type IIB signaling in adult skeletal muscle
Relizani, K. (2014) · theses.fr (ABES) · doi:10.70675/20978d43z02f0z4a1ezb428zf5dab86d9abf
Petkova, M. V. (2016) · theses.fr (ABES) · doi:10.70675/c9ccc0a7z00b1z4264zb141zca90e3bd5543
Morais, R. D. S. (2017) · theses.fr (ABES) · doi:10.70675/5933750czbcdbz4667zb8d3z65c0bec2655f
Dynamique et mécanique de complexes dystrophine-actine-lipides membranaires
Mias‐Lucquin, D. (2018) · theses.fr (ABES) · doi:10.70675/091e2702zc85fz4c91z908cz7e654aa5a3de
Le développement préclinique des tcDNA pour la Dystrophie Musculaire de Duchenne
Aupy, P. (2019) · theses.fr (ABES) · doi:10.70675/308d569bzf97az413bz805fzc8aaca0427df
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.